Dermal fillers - Import export

HERMOSA Dermal Filler is a product designed to temporarily improve wrinkles using hyaluronic acid. The hyaluronic acid used in this product is a raw material that has been cross-linked with homogenized particles with optimal viscoelasticity through Novepharma's proprietary technology, thereby ensuring excellent volume effect for a long time. This material helps soft infusion by lowering the pressure at the time of injection. In addition, the design of the plunger and handles has been improved to suit the various hand sizes of the practitioner. The product also contains a topical anesthetic, which improves the discomfort caused by the procedure. Novepharma manages the raw materials through its own quality control and manufacturing system and strictly complies with international quality regulations including KGMP, ISO 13485 and ISO 9001 for quality assurance of the final product. There is low level of endotoxin and no BDDE residue and it is safe for patients to use.

Swisso Logical Multi-Regenerating Cream fulfills its anti-aging promise thanks to VOLUFORM, a revolutionary patented ingredient that will miraculously replenish the contour of your face, filling fine lines and plumping out wrinkles. Presentation THINK LOGICALLY: MULTI-REGENERATING CREAM IS THE BEST ALTERNATIVE TO DERMAL FILLERS OR INJECTIONS For its outstanding results, Swisso Logical’s Multi-Regenerating Cream has achieved three patents. Now you can fight premature aging caused by loss of collagen, stress and extreme weather conditions with our award-winning multi-regenerating cream and immediately improve comfort of the skin. Suitable for dry to very dry skin. How to use: Morning and/or evening, apply all over the face and neck. Avoid contact in the eyes.

Contact Korea was founded in 2001 and sells and manufactures medical devices. In 2001, the world's No. 1 product, Restylane, was first launched in Korea as an HA filler, pioneering the field of fillers in the cosmetic surgery industry, and developing injection filler for pediatric urinary disorders (VUR). Since 2015, we have participated in research and development and manufacture of medical devices in earnest and developed indirect drug injector, various dermal fillers, and multi-needles and exporting them to 19 countries. And in 2023, we are jointly developing exosomes, a key substance in stem cell culture, with bio-venture company and aim to export 200% growth within two years.